A single-arm, phase II trial assessing the combination of AK105 and anlotinib in first-line treatment for persistent, recurrent, or metastatic cervical cancer

被引：0
|
作者：
Guo, Ruixia [1 ]
Qiu, Haifeng [1 ]
Wang, Qian [1 ]
Su, Ke [1 ]
Chang, Lei [1 ]
Cai, Mingbo [1 ]
Mao, Meng [1 ]
Bian, Aiping [1 ]
机构：
[1] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5530
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Anlotinib Plus Etoposide and Carboplatin as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer: A Single Arm Phase II Trial
    Han, B.
    Zhang, W.
    Zhang, B.
    Chen, Y.
    Zhang, Y.
    Lou, Y.
    Dong, Y.
    Qian, F.
    Zhou, W.
    Yang, Z.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S503 - S503
  • [42] COMBINATION OF NIRAPARIB AND ANLOTINIB IN PATIENTS WITH RECURRENT OR METASTATIC ENDOMETRIAL CANCER: AN OPEN-LABEL, SINGLE-ARM, TWO-STAGE, PHASE II STUDY
    Ren, Yulan
    Lu, Jing
    Tian, Wenjuan
    Li, Haiming
    Wang, Huaying
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A107 - A107
  • [43] TISLELIZUMAB IN COMBINATION WITH ANLOTINIB AS FIRST-LINE TREATMENT FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA: A SINGLE-CENTER, SINGLE-ARM, EXPLORATORY PHASE I I CLINICAL STUDY
    Laoguo, Shixue
    Huang, Huasheng
    Zeng, Jie
    Jiang, Yangfeng
    Liu, Cuizhen
    Mo, Ning
    Zhu, Guangzhi
    Ma, Fuchao
    Peng, Tao
    Yang, Lihua
    Zeng, Zhiming
    Ma, Jie
    HEPATOLOGY, 2023, 78 : S1904 - S1904
  • [44] Anlotinib in patients with recurrent advanced cervical cancer: A prospective single-arm, open-label, phase. trial.
    Wu, Xiaohua
    Zhu, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [45] Anlotinib plus platinum-etoposide as a first-line treatment for extensive-stage small cell lung cancer: A single-arm trial
    Deng, Pengbo
    Hu, Chengping
    Chen, Cen
    Cao, Liming
    Gu, Qihua
    An, Jian
    Qin, Ling
    Li, Min
    He, Baimei
    Jiang, Juan
    Yang, Huaping
    CANCER MEDICINE, 2022, 11 (19): : 3563 - 3571
  • [46] Toripalimab in combination with anlotinib in previously treated recurrent or metastatic nasopharyngeal carcinoma: The interim analysis of the single-arm, phase II TORAL study
    Cai, Q.
    Zou, Q.
    Zhang, Y.
    Xia, Y.
    Liu, P.
    Su, N.
    Wang, J.
    Tian, X.
    ANNALS OF ONCOLOGY, 2023, 34 : S579 - S579
  • [47] COST EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB AS FIRST-LINE TREATMENT FOR PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER IN GREECE
    Yfantopoulos, N.
    Gountas, I
    Swami, S.
    Skroumpelos, A.
    Karokis, A.
    VALUE IN HEALTH, 2023, 26 (12) : S62 - S62
  • [48] A phase II, multicenter, single-arm trial of eribulin as first-line chemotherapy for HER2-negative locally advanced or metastatic breast cancer
    Takashima, Tsutomu
    Tokunaga, Shinya
    Tei, Seika
    Nishimura, Shigehiko
    Kawajiri, Hidemi
    Kashiwagi, Shinichiro
    Yamagata, Shigehito
    Noda, Satoru
    Nishimori, Takeo
    Mizuyama, Yoko
    Sunami, Takeshi
    Tezuka, Kenji
    Ikeda, Katsumi
    Ogawa, Yoshinari
    Onoda, Naoyoshi
    Ishikawa, Tetsuro
    Kudoh, Shinzoh
    Takada, Minoru
    Hirakawa, Kosei
    SPRINGERPLUS, 2016, 5 : 1 - 8
  • [49] Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06)
    Rochlitz, C.
    Ruhstaller, T.
    Lerch, S.
    Spirig, C.
    Huober, J.
    Suter, T.
    Buehlmann, M.
    Fehr, M.
    Schoenenberger, A.
    von Moos, R.
    Winterhalder, R.
    Rauch, D.
    Mueller, A.
    Mannhart-Harms, M.
    Herrmann, R.
    Cliffe, B.
    Mayer, M.
    Zaman, K.
    ANNALS OF ONCOLOGY, 2011, 22 (01) : 80 - 85
  • [50] Sintilimab plus anlotinib as second-line therapy for metastatic or recurrent gallbladder carcinoma (GBC): A single-arm, phase II study
    Cheng, Q.
    Jiang, X.
    ANNALS OF ONCOLOGY, 2022, 33 : S1468 - S1469
12345